These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 33928421)

  • 1. Effects of psilocybin microdosing on awe and aesthetic experiences: a preregistered field and lab-based study.
    van Elk M; Fejer G; Lempe P; Prochazckova L; Kuchar M; Hajkova K; Marschall J
    Psychopharmacology (Berl); 2022 Jun; 239(6):1705-1720. PubMed ID: 33928421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study.
    Marschall J; Fejer G; Lempe P; Prochazkova L; Kuchar M; Hajkova K; van Elk M
    J Psychopharmacol; 2022 Jan; 36(1):97-113. PubMed ID: 34915762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention.
    Petranker R; Anderson T; Maier LJ; Barratt MJ; Ferris JA; Winstock AR
    J Psychopharmacol; 2022 Jan; 36(1):85-96. PubMed ID: 33591231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study.
    Cavanna F; Muller S; de la Fuente LA; Zamberlan F; Palmucci M; Janeckova L; Kuchar M; Pallavicini C; Tagliazucchi E
    Transl Psychiatry; 2022 Aug; 12(1):307. PubMed ID: 35918311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microdosing psychedelics: Motivations, subjective effects and harm reduction.
    Lea T; Amada N; Jungaberle H; Schecke H; Klein M
    Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-blinding citizen science to explore psychedelic microdosing.
    Szigeti B; Kartner L; Blemings A; Rosas F; Feilding A; Nutt DJ; Carhart-Harris RL; Erritzoe D
    Elife; 2021 Mar; 10():. PubMed ID: 33648632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural language signatures of psilocybin microdosing.
    Sanz C; Cavanna F; Muller S; de la Fuente L; Zamberlan F; Palmucci M; Janeckova L; Kuchar M; Carrillo F; García AM; Pallavicini C; Tagliazucchi E
    Psychopharmacology (Berl); 2022 Sep; 239(9):2841-2852. PubMed ID: 35676541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microdosing psychedelics: personality, mental health, and creativity differences in microdosers.
    Anderson T; Petranker R; Rosenbaum D; Weissman CR; Dinh-Williams LA; Hui K; Hapke E; Farb NAS
    Psychopharmacology (Berl); 2019 Feb; 236(2):731-740. PubMed ID: 30604183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.
    Rosenbaum D; Weissman C; Anderson T; Petranker R; Dinh-Williams LA; Hui K; Hapke E
    J Psychopharmacol; 2020 Jun; 34(6):612-622. PubMed ID: 32108529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Set and setting in microdosing: an oft-overlooked principle.
    Hartogsohn I; Petranker R
    Psychopharmacology (Berl); 2022 Dec; 239(12):3771-3777. PubMed ID: 36289109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Motives and Side-Effects of Microdosing With Psychedelics Among Users.
    Hutten NRPW; Mason NL; Dolder PC; Kuypers KPC
    Int J Neuropsychopharmacol; 2019 Jul; 22(7):426-434. PubMed ID: 31152167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychedelic microdosing benefits and challenges: an empirical codebook.
    Anderson T; Petranker R; Christopher A; Rosenbaum D; Weissman C; Dinh-Williams LA; Hui K; Hapke E
    Harm Reduct J; 2019 Jul; 16(1):43. PubMed ID: 31288862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins.
    Rouaud A; Calder AE; Hasler G
    J Psychopharmacol; 2024 Mar; 38(3):217-224. PubMed ID: 38214279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field.
    Polito V; Liknaitzky P
    Neurosci Biobehav Rev; 2022 Aug; 139():104706. PubMed ID: 35609684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microdosing with classical psychedelics: Research trajectories and practical considerations.
    Wong A; Raz A
    Transcult Psychiatry; 2022 Oct; 59(5):675-690. PubMed ID: 36317302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research.
    Polito V; Liknaitzky P
    J Psychopharmacol; 2024 Jun; ():2698811241254831. PubMed ID: 38877715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders.
    Lea T; Amada N; Jungaberle H; Schecke H; Scherbaum N; Klein M
    Psychopharmacology (Berl); 2020 May; 237(5):1521-1532. PubMed ID: 32043165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls.
    Rootman JM; Kiraga M; Kryskow P; Harvey K; Stamets P; Santos-Brault E; Kuypers KPC; Walsh Z
    Sci Rep; 2022 Jun; 12(1):11091. PubMed ID: 35773270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microdosing psychedelics: More questions than answers? An overview and suggestions for future research.
    Kuypers KP; Ng L; Erritzoe D; Knudsen GM; Nichols CD; Nichols DE; Pani L; Soula A; Nutt D
    J Psychopharmacol; 2019 Sep; 33(9):1039-1057. PubMed ID: 31303095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peak experiences of psilocybin users and non-users.
    Cummins C; Lyke J
    J Psychoactive Drugs; 2013; 45(2):189-94. PubMed ID: 23909006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.